In the past week, COGT stock has gone up by 14.31%, with a monthly decline of -14.68% and a quarterly plunge of -19.35%. The volatility ratio for the week is 8.76%, and the volatility levels for the last 30 days are 6.54% for Cogent Biosciences Inc. The simple moving average for the past 20 days is -3.46% for COGT’s stock, with a -17.25% simple moving average for the past 200 days.
Is It Worth Investing in Cogent Biosciences Inc (NASDAQ: COGT) Right Now?
The 36-month beta value for COGT is at 1.60. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for COGT is 94.82M, and currently, shorts hold a 11.39% of that float. The average trading volume for COGT on March 06, 2025 was 1.58M shares.
COGT) stock’s latest price update
The stock price of Cogent Biosciences Inc (NASDAQ: COGT) has jumped by 6.97 compared to previous close of 7.17. Despite this, the company has seen a gain of 14.31% in its stock price over the last five trading days. globenewswire.com reported 2025-02-27 that 65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.
Analysts’ Opinion of COGT
Robert W. Baird, on the other hand, stated in their research note that they expect to see COGT reach a price target of $8, previously predicting the price at $14. The rating they have provided for COGT stocks is “Neutral” according to the report published on February 26th, 2024.
Citigroup gave a rating of “Buy” to COGT, setting the target price at $11 in the report published on February 08th of the previous year.
COGT Trading at -5.53% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.18% of loss for the given period.
Volatility was left at 6.54%, however, over the last 30 days, the volatility rate increased by 8.76%, as shares sank -17.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.39% upper at present.
During the last 5 trading sessions, COGT rose by +14.31%, which changed the moving average for the period of 200-days by -0.65% in comparison to the 20-day moving average, which settled at $7.94. In addition, Cogent Biosciences Inc saw -1.67% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at COGT starting from Pinnow Cole, who purchase 43,750 shares at the price of $7.60 back on Jan 14 ’25. After this action, Pinnow Cole now owns 45,848 shares of Cogent Biosciences Inc, valued at $332,412 using the latest closing price.
Stock Fundamentals for COGT
The total capital return value is set at -1.01. Equity return is now at value -99.54, with -79.79 for asset returns.
Based on Cogent Biosciences Inc (COGT), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -11.9.
Currently, EBITDA for the company is -275.94 million with net debt to EBITDA at 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.32.
Conclusion
In conclusion, Cogent Biosciences Inc (COGT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
